Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 7/20 | 0.76 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.73 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.64 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9829296 | 0.91 | GPR132 (0.67) | GPR132GPR139CMKLR2CMKLR1PTPN1 | |
| SCHEMBL9829301 | 0.91 | GPR132 (0.67) | GPR132GPR139CMKLR2CMKLR1PTPN1 | |
| SCHEMBL4178541 | 0.91 | GPR139 (0.72) | GPR132GPR139CMKLR2CMKLR1CTSL | |
| SCHEMBL31389144 | 0.91 | GPR139 (0.72) | GPR132GPR139CMKLR2CMKLR1CTSL | |
| SCHEMBL18114395 | 0.91 | GPR132 (0.81) | GPR132GPR139CMKLR2CMKLR1PTPN1 | |
| SCHEMBL18127321 | 0.86 | GPR132 (0.61) | GPR132GPR139CMKLR2CMKLR1PTPN1 | |
| SCHEMBL28803950 | 0.86 | GPR139 (0.66) | GPR132GPR139CMKLR2CMKLR1PTPN1 | |
| SCHEMBL28804114 | 0.86 | GPR139 (0.66) | GPR132GPR139CMKLR2CMKLR1PTPN1 | |
| SCHEMBL29756558 | 0.86 | GPR139 (0.66) | GPR132GPR139CMKLR2CMKLR1PTPN1 | |
| SCHEMBL28803953 | 0.86 | GPR139 (0.66) | GPR132GPR139CMKLR2CMKLR1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | TAS2R10, TAS2R50, TAS2R8 | GPR132 246/4885GPR139 238/4885CMKLR2 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.